Please assess the completion status of the following clinical trial:

Trial Title: Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are 18 to 65 years of age, inclusive, at the time of informed consent (outpatients only), with a diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and confirmed by both the M.I.N.I. for Schizophrenia and Psychotic Disorders Studies, and an adequate clinical psychiatric evaluation.~* Have a CGI-S score of ≤ 4 (moderately ill) at screening and baseline.~* Have a score of ≤ 4 (moderate) on PANSS item G8 (uncooperativeness) at screening and baseline.~* Have a BIS-11 score of ≥ 50 at screening and baseline.~* Willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.~* Are stable on their current oral antipsychotic medication (no changes within the last month) and are able to meet protocol-required washouts of their current antipsychotic medication.~* Have received previous outpatient antipsychotic treatment at an adequate dose (at least minimal recommended dose for the treatment of schizophrenia according to the manufacturer labeling) for an adequate duration (at least 6 weeks) and showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months, according to the investigator's opinion.~* Subjects with eyesight that is sufficient to be able to see visual displays, or correctable with magnet-compatible glasses or contact lenses.~* Subjects fluent in English~Exclusion Criteria:~* Are presenting with schizophreniform or with a first episode of schizophrenia based on the clinical judgment of the investigator.~* Have been hospitalized for psychotic symptoms within the previous 6 months.~* Have a current DSM-IV-TR Axis I primary diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder (OCD) or panic disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders, or mental retardation.~* Have worsening of ≥ 20% in total PANSS score between the screening and baseline assessments.~* Experiencing a deterioration in clinical status or an acute exacerbation of schizophrenia in the opinion of the Investigator.~* Experiencing acute onset of clinically significant depressive symptoms within the past 30 days, according to the investigator's opinion.~* Answer Yes on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Answer Yes on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria for this C-SSRS Item 5 occurred within the last 6 months OR Answer Yes on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR who, in the opinion of the investigator, present a serious risk of suicide.~* Have a history of stroke.~* Contraindications to magnetic resonance imaging (MRI) such as metal prostheses, pacemakers, claustrophobia, movement disorders, waist circumference more than 56 inches or head circumference more than 29 inches, color blindness, significant tremors, or history of head injury or prolonged unconsciousness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole 2 mg (Type: EXPERIMENTAL): Brexpiprazole 2 mg/day, once daily dose, tablet, orally
- Brexpiprazole 4 mg (Type: EXPERIMENTAL): Brexpiprazole 4 mg/day, once daily dose, tablet, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).